Rezolute Announces Alignment With FDA On Streamlined Design For Ongoing Phase 3 Trial Of Ersodetug In Tumor Hyperinsulinism
Rezolute Inc RZLT.O:
REZOLUTE ANNOUNCES ALIGNMENT WITH FDA ON STREAMLINED DESIGN FOR ONGOING PHASE 3 TRIAL OF ERSODETUG IN TUMOR HYPERINSULINISM
REZOLUTE INC - TOPLINE DATA EXPECTED IN SECOND HALF OF 2026 - SEC FILING
REZOLUTE INC: FDA ALSO CONFIRMED THAT REZOLUTE S PIVOTAL SUNRIZE TRIAL IN CONGENITAL HI, WHICH IS ON TRACK TO REPORT TOPLINE RESULTS IN DECEMBER 2025
Source text: [ID:n0001104659-25-085892]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Meme Stocks Reappear. Avis Shares Reach New Highs Amid Short Squeeze. Can Retail Investors Still Buy?

SpaceX IPO: Musk Weighs $60 Billion Cursor Deal, and Can It Save xAI?

Intel Q1 2026 Earnings Preview: The Rally is Ahead of the Fundamentals

SK Hynix Q1 2026 Earnings Preview: Memory Chip Prices Surge, Profit Set to Double

Intel Foundry Gains ‘High-Profile’ Customer, Tesla Becomes First Major Customer for 14A Technology

Tradingkey






